Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin

The most frequent and the most troublesome adverse effect of interferon plus ribavirin‐based therapy is anaemia. The aim of this analysis was to determine the incidence and risk factors of anaemia (Hb 

Saved in:
Bibliographic Details
Published in:Journal of viral hepatitis 2007-09, Vol.14 (9), p.639-644
Main Authors: Bani-Sadr, F., Goderel, I., Penalba, C., Billaud, E., Doll, J., Welker, Y., Cacoub, P., Pol, S., Perronne, C., Carrat, F.
Format: Article
Language:English
Subjects:
Adult
anaemia
Anemia - etiology
Anti-HIV Agents - adverse effects
Anti-HIV Agents - therapeutic use
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Drug Therapy, Combination
Female
Hepatitis C virus
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - drug therapy
HIV Infections - complications
HIV Infections - drug therapy
Human immunodeficiency virus
human immunodeficiency virus/hepatitis C virus coinfection
Humans
Interferon-alpha - adverse effects
Interferon-alpha - therapeutic use
Kaplan-Meier Estimate
Male
peginterferon
Polyethylene Glycols
protease inhibitor
Recombinant Proteins
ribavirin
Ribavirin - adverse effects
Ribavirin - therapeutic use
Risk Factors
zidovudine
Zidovudine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The most frequent and the most troublesome adverse effect of interferon plus ribavirin‐based therapy is anaemia. The aim of this analysis was to determine the incidence and risk factors of anaemia (Hb 
ISSN:1352-0504
1365-2893
DOI:10.1111/j.1365-2893.2007.00846.x